Sinonasal carcinoma
Conditions
Interventions
Neoadjuvant toripalimab combined with chemotherapy group:Tislelizumab + neoadjuvant chemotherapy
Sponsors
Eye & ENT hospital of Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age >18 years and 2000/mm^3, platelet count >100,000/mm^3; 9. Pre-treatment liver and kidney function tests meeting the following conditions: bilirubin 60 ml/min; 10. Signed informed consent before the start of the study.
Exclusion criteria
Exclusion criteria: 1. Malignant tumors of the nasal cavity and paranasal sinuses with pathological types other than squamous cell carcinoma or undifferentiated carcinoma; 2. Cases not confirmed through multidisciplinary team (MDT) discussion; 3. Unsuitable for enhanced MRI imaging evaluation; 4. Cases staged as I-II or IVC according to the UICC/AJCC 8th edition staging criteria; 5. Clinical or imaging evidence of distant metastasis, or suspected evidence thereof; 6. History of radiotherapy for head and neck malignancies or presence of multiple primary tumors (excluding basal cell carcinoma of the skin); 7. Positive pregnancy test in women of childbearing age; 8. Concomitant diseases or conditions that affect the patient's normal enrollment or safety during the study; 9. Active psychiatric disorders or other psychological conditions affecting the patient's ability to provide informed consent and understand the study; 10. Uncontrolled active infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate, ORR; | — |
Countries
China
Contacts
Public Contactwangli
Eye & ENT hospital of Fudan University
Outcome results
None listed